#United States #NASDAQ #Dividend #Minneapolis #Bio-Techne

Bio-Techne Corporation Declares Dividend

On November 5, 2025, Bio-Techne Corporation, a leading global life sciences firm listed on the NASDAQ under the symbol TECH, made an important announcement regarding its shareholder returns. The Board of Directors has officially declared a quarterly dividend of $0.08 per share for the quarter that ended on September 30, 2025. This decision underscores the company’s commitment to providing value to its shareholders and reinforces its operational strength.

The dividend is set to be distributed on November 28, 2025, to all common shareholders recorded on November 17, 2025. As part of its ongoing commitment to shareholders, Bio-Techne has indicated that future cash dividends will continue to be evaluated by the Board on a quarterly basis. This approach is aimed at maintaining a steady return for investors while ensuring that the company retains adequate capital for growth and operational needs.

Bio-Techne Corporation, based in Minneapolis, specializes in delivering cutting-edge tools and bioactive reagents essential for the research and clinical diagnostic sectors. Its diverse product range aids scientific inquiries into various biological processes, including the identification and progression of diseases, thereby facilitating drug discovery and enabling precise clinical testing. Over the past fiscal year, the company has notably achieved over $1.2 billion in net sales, backed by a dedicated workforce of approximately 3,100 employees globally. This robust financial performance is a testament to Bio-Techne’s strategic focus on innovation and market expansion.

As a prominent player in the life sciences arena, Bio-Techne offers a vast portfolio of thousands of products that cater to the needs of researchers, clinicians, and diagnostic professionals worldwide. Interested parties can learn more about their offerings and company initiatives by visiting their official website at www.bio-techne.com.

Forward-Looking Statements

It is important to note that Bio-Techne's communications may include forward-looking statements as defined by the Private Securities Litigation Reform Act. These statements entail certain risks and uncertainties that could impact the company's actual performance compared to what is projected. Factors such as market conditions, currency fluctuations, and competitive pricing in the biotechnology sphere may affect the company’s future operations and stock performance.

Investors are advised to exercise caution and not rely solely on these forward-looking statements when making investment decisions. For a comprehensive understanding of potential risks, stakeholders are encouraged to refer to the